IPO Report

The Xinhua IPO could be in jeopardy  if  the Chinese   market correction turns into an extended down turn.

"The fate of this deal will depend on whether or not...China sell-off spirals into a more prolonged downturn in the Chinese stock market, which would definitely impact investor sentiment," said Paul Bard of Renaissance Capital in an interview with CBS Marketwatch.

Xinhua Finance Media plans to offer 23.1 million American depositary shares at an estimated price of $12 to $14 each in a bid to raise about $300 million with underwriters J.P. Morgan, UBS Investment Bank and CIBC World Markets.

The company operates print media, TV and radio programming distributed in China. Xinhua reported 2006 net income of $3.3 million and revenue of $59 million.

Xinhua Finance Media Limited             (NASDAQ  XFML) IPO

China's Xinhua Finance Media Ltd. filed with U.S. regulators on Wednesday for an initial public offering of 23.1 million American Depositary Shares at an estimated price of $12 to $14 each.

The company, which produces business and financial news programming, said in a registration statement filed with the U.S. Securities and Exchange Commission that it planned to sell 17.3 million ADS, with stockholders selling an additional 5.8 million.

Xinhua said it expected to receive about $204 million in net proceeds from the IPO. It will use $50 million of the funds to repay debt, and the rest for acquisitions, working capital and other general corporate purposes

OncoGenex IPO Week of 2/26/07

Biopharmaceutical company OncoGenex Technologies Inc. set the terms of its pending initial public offering at 4.5 million shares with an estimated price range of $10 to $12 a share.

In mid-December, the Vancouver, British Columbia-based cancer therapy company filed an IPO to sell up to $48 million in common stock but didn't detail the terms of the offering. The company now estimates the IPO to be worth up to $62.1 million, according to a filing with the Securities and Exchange Commission.

OncoGenex said it plans to use net proceeds from the IPO to fund the further development and expansion of its product candidates and for other working capital and general corporate purposes.

The underwriters may also purchase up to an additional 675,000 shares to meet demand, Monday's SEC filing said.

The company plans to list its stock on the Nasdaq Global Market under the symbol "OGXI," and on the Toronto Stock Exchange under the symbol "OGX."

Rosetta Genomics IPO Week of 2/26/07

Rosetta Genomics Ltd. on Tuesday increased the number of shares but cut the estimated price range for its planned initial public offering.

The Israeli company now plans to sell 3.75 million shares at $7.50 to $8.50 each, according to an amended prospectus filed with the U.S. Securities and Exchange Commission. It previously planned to offer 3 million shares at $11 to $13 each.

The IPO's underwriters have an option to buy up to 562,500 additional shares to cover overallotments, up from a previously planned 450,000 shares, the filing said.

Rosetta Genomics is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs.

The company said it intends to use the net proceeds from the IPO for product research and development, for licensing and protection of its intellectual-property rights, for business development and for general corporate purposes, including working capital.